| Date | Title | | | 11/16/09 | Amgen to Present at Lazard Capital Healthcare Conference|
THOUSAND OAKS, Calif., Nov. 16 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) will participate in the Lazard Capital Healthcare Conference on Wednesday, Nov. 18, 2009, at the St. Regis Hotel in New York City, beginning at 9:30 a.m. Eastern Time. Arvind Sood, vice president, Investor Relations at Amgen, will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen's Web site, www.amgen.com, under Investors.
Information re... |
|  | | 11/12/09 | Amgen to Present at 18th Annual Credit Suisse Healthcare Conference|
THOUSAND OAKS, Calif., Nov. 12 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) will participate in the 18th Annual Credit Suisse Healthcare Conference on Thursday, Nov. 12, 2009, at the Biltmore Hotel in Phoenix, Ariz., beginning at 9:30 a.m. Mountain Time. Robert A. Bradway, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen's Web site, www.amgen.com,... |
| | | 11/05/09 | Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer| Phase 3 Results Reinforce Importance of KRAS Status
THOUSAND OAKS, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that the Phase 3 PRIME "203" trial evaluating Vectibix (R) (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival. Earlier this year, it was announced that the trial met its primary endpoin... |
| | | 11/04/09 | Call for Applications: The Amgen Award for Science Teaching Excellence| 34 Outstanding Teachers Will Be Recognized in Communities Where Amgen Operates
THOUSAND OAKS, Calif., Nov. 4 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that it now invites applications for its 19th annual Amgen Award for Science Teaching Excellence (AASTE). This award is designed to recognize and honor extraordinary science teachers at the K-12 level who significantly impact their students through exemplary science teaching and who achieve demonstrated results in student le... |
| | | 10/30/09 | Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints| Aranesp(R) (Darbepoetin Alfa) Did Not Reduce the Risk of Mortality, Cardiovascular Morbidity, or End Stage Renal Disease
THOUSAND OAKS, Calif., Oct. 30 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced the publication of results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp® Therapy), a large, randomized, double-blind, placebo-controlled, Phase 3 pivotal study of patients with chronic kidney disease (CKD) not on dialysis, moderate anemia and type-2 di... |
| | | 10/21/09 | Amgen's Third Quarter 2009 Adjusted Earnings Per Share Increased 21 Percent to $1.49| Third Quarter 2009 Revenue Decreased 2 Percent to $3.8 Billion
THOUSAND OAKS, Calif., Oct. 21 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS) of $1.49 for the third quarter of 2009, an increase of 21 percent compared to $1.23 for the third quarter of 2008. Adjusted net income increased 16 percent to $1,518 million in the third quarter of 2009 compared to $1,308 million in the third quarter of 2008.
Total revenue decreased 2... |
| | | 10/19/09 | Amgen Provides Update on Status of Prolia(TM) (Denosumab) Biologics License Application (BLA) Submitted to the U.S. Food and Drug Administration (FDA)| THOUSAND OAKS, Calif., Oct 19, 2009 /PRNewswire-FirstCall via COMTEX/ -- Amgen Inc. (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the Biologic License Applications (BLA) for Prolia(TM) (denosumab) in the treatment and prevention of postmenopausal osteoporosis.
The FDA issues Complete Response Letters to request additional information needed to complete the review of applications for product approval.
The Complete Res... |
| | | 10/16/09 | Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting| New Data Contribute to Existing Body of Knowledge About ENBREL
THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Oct. 16 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) and Pfizer (NYSE: PFE), today announced new scientific data about ENBREL being presented at the 2009 American College of Rheumatology (ACR) Scientific Meeting in Philadelphia, Pa., from Oct. 17-21, 2009. These presentations contribute to data generated through 17 years of collective clinical experience.
"The clinical data being p... |
| | | 10/15/09 | Amgen Announces Webcast of 2009 Third Quarter Financial Results|
THOUSAND OAKS, Calif., Oct. 15 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that it plans to report its third quarter financial results on Wednesday, Oct. 21, 2009 after the close of the financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. Pacific Time. Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen's senior management team.
... |
| | | 09/24/09 | Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in First-Line Metastatic Colorectal Cancer| THOUSAND OAKS, Calif., Sept 24, 2009 /PRNewswire-FirstCall via COMTEX/ -- Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '203' trial evaluating Vectibix(R) (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as the first-line treatment of metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved median progression-free survival (PFS) by 1.6 months (9.6 versus 8.0 months for patients treated with FOLFOX alone,... |
| | | 09/22/09 | Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients|
THOUSAND OAKS, Calif., Sept. 22 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 2,046 patients with advanced breast cancer that met its primary and secondary endpoints and demonstrated superior efficacy compared to Zometa. These results were presented today during the Presidential Session at the 2009 ECCO 15 - ESMO 34 European Mul... |
| | | 09/22/09 | Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in Second-Line Metastatic Colorectal Cancer|
THOUSAND OAKS, Calif., Sept. 22 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC. These results were presented at the 2009 ECCO 15 - ESMO 34 Europe... |
| | | 09/21/09 | Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases|
THOUSAND OAKS, Calif., Sept. 21 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3 trial evaluating denosumab administered subcutaneously versus Zometa(R) (zoledronic acid) administered as an intravenous infusion in the treatment of bone metastases in 1,776 advanced cancer patients with solid tumors (not including breast and prostate cancer) or multiple myeloma. These results were presented today at the 2009 ECCO 15 - ESMO 34 European Mult... |
| | | 09/17/09 | Amgen to Present at the UBS Global Life Sciences Conference|
THOUSAND OAKS, Calif., Sept. 17 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) will participate in the UBS Global Life Sciences Conference on Monday, Sept. 21, 2009, at the Grand Hyatt in New York City, beginning at 8:30 a.m. Eastern Time. Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen's Web site, www.amgen.com, un... |
| | | 09/16/09 | Amgen Scholars Europe Programme Convenes Undergraduates From 15 Countries for Innovative Science Research|
Symposium Offers Unique Opportunity to Meet Peers and Leading Scientists; Discuss Hands-On Summer Research Projects
CAMBRIDGE, England, September 16 /PRNewswire/ -- This week, 59 undergraduates with diverse cultural and educational backgrounds will meet at the University of Cambridge for the first Amgen Scholars European Symposium with the common goal of discussing their potential as the future generation of leading scientists.
The first Amgen Scholars Europe class represents 35 dif... |
| | | 09/16/09 | Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 - ESMO 34 Congress| Key Denosumab and Vectibix(R) (Panitumumab) Data to be Presented
THOUSAND OAKS, Calif., Sept. 16 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced it will present detailed data from four Phase 3 studies as well as other data at the ECCO 15 - ESMO 34 European Multidisciplinary Congress, September 20 - 24, 2009 in Berlin, Germany.
Researchers will present data from two Phase 3 head-to-head studies evaluating denosumab versus Zometa(R) (zoledronic acid) for the treatment of b... |
| | | 09/15/09 | Appeals Court Affirms Patent Infringement Rulings Against Roche's peg-EPO Product|
THOUSAND OAKS, Calif., Sept. 15 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that the Court of Appeals for the Federal Circuit affirmed the Massachusetts District Court's decision that Roche's peg-EPO product, Mircera, infringes four Amgen patents ('868, '698, '933 and '422) relating to recombinant erythropoietin (EPO) and processes for making it. Regarding a fifth patent ('349), the Federal Circuit reversed the holding of non-infringement by the District Court and remande... |
| | | 09/14/09 | Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference|
THOUSAND OAKS, Calif., Sept. 14 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) will participate in the Bank of America Merrill Lynch Global Healthcare Conference on Thursday, Sept. 17, 2009, in London, beginning at 9:50 a.m. Greenwich Mean Time. Amgen executives will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen's Web site, www.amgen.com, under Investors.
Information regarding presentation time, webcast ava... |
| | | 09/13/09 | Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis| Poor Adherence Can Lead to Higher Fracture Risk, More Frequent Hospital Admissions and Higher Medical Costs
DENVER, Sept. 13 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced the presentation of data highlighting the links between medication satisfaction, adherence to therapy and fracture risk reduction among women with postmenopausal osteoporosis. The data were presented at the 31st annual meeting of the American Society for Bone Mineral Research (ASBMR).
"These da... |
| | | 09/11/09 | Amgen to Present at the Morgan Stanley Global Healthcare Unplugged Conference|
THOUSAND OAKS, Calif., Sept. 11 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) will participate in the Morgan Stanley Global Healthcare Unplugged Conference on Monday, Sept. 14, 2009, at the Grand Hyatt hotel in New York City, beginning at 12:00 p.m. Eastern Time. Amgen Chairman and CEO Kevin Sharer will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen's Web site, www.amgen.com, under Investors.
Informati... |
| | | 09/10/09 | Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting|
THOUSAND OAKS, Calif., Sept. 10 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that new data will be presented on the burden of osteoporosis, current osteoporosis treatment challenges and Prolia(TM) (denosumab) at the 2009 American Society for Bone and Mineral Research (ASBMR) annual meeting in Denver from Sept. 11-15, 2009. Prolia currently is being evaluated by regulatory bodies in the United States (U.S.), the European Union, Switzerland, Australia and Canada as a potent... |
| | | 09/10/09 | Edie Falco and Cynthia Nixon Appear in New Stand Up To Cancer(TM) PSAs Designed to Educate Cancer Patients About the Importance Of Lowering One's Risk of Infection During Treatment|
LOS ANGELES, Sept. 10 /PRNewswire/ -- Award-winning actresses Edie Falco and Cynthia Nixon appear in a new Stand Up To Cancer(TM) (SU2C) public service campaign to educate cancer patients and their loved ones about the increased risk of infection during cancer treatment and the importance of learning how to manage one's risk.
To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/amgen/39907/
(Photo: http://www.newscom.com/cgi-bin/prnh/20090910/NY73333 )
Often patients ar... |
| | | 09/09/09 | Amgen Named Presenting Sponsor of The Dempsey Challenge: A Journey For Hope|
LEWISTON, Maine and THOUSAND OAKS, Calif., Sept. 9 /PRNewswire-FirstCall/ -- Amgen has signed on as the presenting sponsor of The Dempsey Challenge: A Journey for Hope, a cycling and 5K fundraising event scheduled for October 4 in Lewiston, Maine. The event supports The Patrick Dempsey Center for Cancer Hope & Healing at Central Maine Medical Center.
The sponsorship provides an opportunity to expand Amgen's Breakaway from Cancer((R)) initiative, which aims to increase awareness of the ... |
| | | 09/08/09 | Amgen to Present at the Thomas Weisel Healthcare Conference|
THOUSAND OAKS, Calif., Sept. 8 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) will participate in the Thomas Weisel Healthcare Conference on Friday, Sept. 11, 2009, at the Four Seasons in Boston, Mass. beginning at 8:35 a.m. Eastern Time. Roy Baynes, M.D. Ph.D., vice president of Global Development for Amgen, will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen's Web site, www.amgen.com, under Investors.
Inform... |
| | | 09/04/09 | Amgen to Present at the Baird Healthcare Conference|
THOUSAND OAKS, Calif., Sept. 4 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) will participate in the Baird Healthcare Conference on Thursday, Sept. 10, 2009, at the Four Seasons in New York City, beginning at 10:00 a.m. Eastern Time. Roy Baynes, M.D. Ph.D., vice president of Global Development, for Amgen, will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen's Web site, www.amgen.com, under Investors.
Informatio... |
| | | 09/02/09 | Tim Gunn Hosts Addressing Psoriasis(TM) Fashion Show to Raise Awareness of Psoriasis| Eight Contest Winners Model Custom-Designed Outfits to Show that Moderate to Severe Plaque Psoriasis Does Not Impact Their Personal Style
NEW YORK, Sept. 2 /PRNewswire/ -- Today, Tim Gunn, television host and fashion consultant ("Project Runway," "Tim Gunn's Guide to Style") and chief creative officer of Liz Claiborne, Inc., is hosting the Addressing Psoriasis(TM) Fashion Show, sponsored by Amgen and Wyeth, in New York City. The fashion show recognizes people with moderate to seve... |
| | | 08/25/09 | Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes| No Statistically Significant Difference in Cardiovascular and Renal Composite Endpoints Between Aranesp and Placebo
THOUSAND OAKS, Calif., Aug. 25 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that in a large, randomized, double-blind, placebo-controlled, Phase 3 study of patients with chronic kidney disease (CKD) (not requiring dialysis), anemia and type-2 diabetes (the Trial to Reduce Cardiovascular Endpoints with Aranesp((R)) Therapy, or TREAT), treatment of anemia wit... |
| | | 08/17/09 | Vectibix(R) Significantly Improved Progression-Free Survival in Second-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer| Second Prospective Phase 3 Vectibix Combination Chemotherapy Trial to Show
Progression-Free Survival Advantage in KRAS Wild-Type Population
THOUSAND OAKS, Calif., Aug. 17 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN) today announced positive top-line results from a Phase 3 trial
evaluating Vectibix (panitumumab) in combination with FOLFIRI (an
irinotecan-based chemotherapy) as a second-line treatment in 1,186 patients
with metastatic colorectal cancer (mCRC). The c... |
| | | 08/13/09 | Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting| THOUSAND OAKS, Calif., Aug 13, 2009 /PRNewswire-FirstCall via COMTEX/ -- Amgen Inc. (Nasdaq: AMGN) issued the following statement on the outcome of today's meeting with the U.S. Food and Drug Administration (FDA) Advisory Committee for Reproductive Health Drugs (ACRHD) to review the potential use of Prolia(TM) (denosumab) for the prevention and treatment of postmenopausal osteoporosis and the prevention and treatment of bone loss in patients undergoing hormone ablation for either prostate cancer... |
| | | 08/13/09 | Amgen to Discuss Denosumab Data at Today's Advisory Committee for Reproductive Health Drugs| --Committee to Review Denosumab in Women with Postmenopausal Osteoporosis and in Patients Undergoing Hormone Ablation Therapy for Either Prostate or Breast CancerTHOUSAND OAKS, Calif., Aug 13, 2009 /PRNewswire-FirstCall via COMTEX/ -- Amgen Inc. (Nasdaq: AMGN) today will summarize data from the submitted Biologic License Applications (BLAs) for denosumab for the prevention and treatment of postmenopausal osteoporosis and the prevention and treatment of bone loss in breast and prostate cancer pat... |
| | | 08/11/09 | Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss| Twice-Yearly Administration of Denosumab Resulted in 68 Percent Reduction in
Risk for a Vertebral Fracture and 40 Percent Reduction in Risk for a Hip
Fracture in Women with Postmenopausal Osteoporosis
Denosumab Administered Twice-Yearly Reduced the Incidence of New Vertebral
Fractures by 62 Percent in Men with Non-Metastatic Prostate Cancer Undergoing
Androgen Deprivation Therapy
THOUSAND OAKS, Calif., Aug. 11 /PRNewswire-FirstCal... |
| | | 08/06/09 | Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer| Pivotal Study Meets Primary Endpoint of Progression-Free Survival in Wild-Type
KRAS
Population
Phase 3 Results Reinforce Importance of KRAS Testing
THOUSAND OAKS, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN) today announced that Vectibix (panitumumab), administered in
combination with FOLFOX (an oxaliplatin-based chemotherapy), significantly
prolonged progression-free survival (PFS) compared with FOLFOX alone in the
... |
| | | 08/04/09 | Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor (TNF) Blockers| THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Aug. 4 /PRNewswire-FirstCall/
-- Amgen (Nasdaq: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE:
WYE), issued a statement in response to the Food and Drug Administration (FDA)
announcement regarding the results of a safety review of Tumor Necrosis Factor
(TNF) blockers [marketed as Remicade (infliximab), Enbrel (etanercept),
Humira (adalimumab), Cimzia (certolizumab pegol) and Simponi (golimumab)].
This safety review was the ... |
| | | 08/03/09 | Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)| Second of Three Pivotal Phase Three Bone Metastases Trials Meets Primary
Endpoint
Denosumab Delayed Time to Skeletal Related Events
THOUSAND OAKS, Calif., Aug. 3 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN) today announced positive top-line results from a pivotal Phase 3
head-to-head trial evaluating denosumab administered subcutaneously versus
Zometa (zoledronic acid) administered as an intravenous (IV) infusion in the
... |
| | | 07/27/09 | Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)| Amgen to Retain Full Rights for Denosumab in the United States and Canada and
for Oncology Indications in Europe
GlaxoSmithKline Will Commercialize Denosumab for PMO and Oncology in Emerging
Markets
THOUSAND OAKS, Calif. and LONDON, July 27 /PRNewswire-FirstCall/ -- Amgen
(Nasdaq: AMGN) and GlaxoSmithKline (GSK) today announced a collaboration in
which the companies will share commercialization of Amgen's monoclona... |
| | | 07/27/09 | Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29| Second Quarter 2009 Revenue Decreased 1 Percent to $3.7 Billion
Second Quarter 2009 GAAP Earnings Per Share Increased 49 Percent to $1.25
2009 Total Revenue Trending Towards Upper End of Current Guidance Range of
$14.4-$14.8 Billion
2009 Adjusted Earnings Per Share Guidance Range of $4.55-$4.75 Raised to
$4.80-$4.95
THOUSAND OAKS, Calif., July 27 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN) r... |
| | | 07/23/09 | Amgen Announces Webcast of 2009 Second Quarter Financial Results| THOUSAND OAKS, Calif., July 23 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN) today announced that it plans to report its second quarter financial
results on Monday, July 27, 2009 after the close of the financial markets. The
announcement will be followed by a conference call with the investment
community at 2 p.m. Pacific Time. Participating in the call from Amgen will
be Kevin Sharer, chairman and chief executive officer, and other members of
Amgen's senior management team.
Liv... |
| | | 07/20/09 | Amgen Scholars Discover Their Potential During Summer Science Research Program and National Symposium| THOUSAND OAKS, Calif., July 20, 2009 /PRNewswire-FirstCall via COMTEX/ -- From July 18-20, more than 260 of the country's brightest undergraduate students met at UCLA for the third annual Amgen Scholars U.S. Symposium designed to bring together program participants and help them apply their science research experiences into future science careers.
The three-day symposium is a key component of the Amgen Scholars Program, a $27.5 million initiative that provides undergraduates the opportunity for... |
| | | 07/17/09 | Amgen Announces KRAS Safety Update to U.S. Prescribing Information for Vectibix(R) (Panitumumab)| Class Labeling Recognizes KRAS as a Predictive Biomarker for anti-EGFr
Antibody Monotherapy in Metastatic Colorectal Cancer
Results from First Pivotal Trials Prospectively Evaluating KRAS Utility in
Combination Therapy Expected In Third Quarter 2009
THOUSAND OAKS, Calif., July 17 /PRNewswire-FirstCall/ -- Amgen Inc.
(Nasdaq: AMGN) today announced the U.S. Food and Drug Administration (FDA) has
approved revisions to the U.S. prescribing informa... |
| | | 07/09/09 | Amgen Appoints Rebecca M. Henderson to the Company's Board of Directors| THOUSAND OAKS, Calif., July 9 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN) announced today that its Board of Directors has appointed Rebecca M.
Henderson, Ph.D., to the Company's Board. Dr. Henderson, 48, has recently
joined the faculty at the Harvard Business School, having been the Eastman
Kodak LFM Professor of Management at the Massachusetts Institute of Technology
(MIT) Sloan School since 1999. She specializes in technology strategy and the
broader strategic problems faced by f... |
| | | 07/07/09 | Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases| Denosumab Significantly Delayed the Time to the First Skeletal Related Event
and Significantly Reduced First and Subsequent Skeletal Related Events
Compared to Zometa
First of Three Pivotal Oncology Trials Comparing Denosumab to Zometa in the
Advanced Cancer Setting Meets Primary and Secondary Endpoints
THOUSAND OAKS, Calif., July 7 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN) today announced that a pivotal, Phase 3, head-to-head trial eva... |
| | | 07/06/09 | Winners of the Addressing Psoriasis(TM) Contest Selected to Walk the Runway in New York City Fashion Show Hosted by Tim Gunn |
Eight Inspiring People Will Model Custom-Designed Outfits Created by Emerging Talent from the Fashion Institute of Technology
NEW YORK, July 6 /PRNewswire/ -- Amgen and Wyeth today announced the eight winners of the Addressing Psoriasis(TM) contest, which recognizes people with moderate to severe plaque psoriasis who have tried not to allow the condition to inhibit their personal style. The winners will help raise public awareness of the condition by walking the runway in the A... |
| | | 06/22/09 | Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August| Advisory Committee to Review Denosumab Data
THOUSAND OAKS, Calif., June 22 /PRNewswire-FirstCall/ -- Amgen Inc.
(Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration
(FDA) has asked the company to participate in a meeting of the Reproductive
Health Drugs Advisory Committee (RHDAC) on Aug. 13, 2009. The RHDAC will
review data supporting the Biologics License Application (BLA) for denosumab,
a RANK Ligand inhibitor for which Amgen is seeking approval for preventi... |
| | | 06/17/09 | 34 Outstanding Teachers and Schools Receive $10,000 Amgen Award for Science Teaching Excellence|
2009 Awardees Recognized in Amgen Communities Across North America
THOUSAND OAKS, Calif., June 17, 2009 /PRNewswire-FirstCall via COMTEX/ Amgen (Nasdaq: AMGN) today announced the 34 science teachers in the United States (U.S.), Canada and Puerto Rico who are this year's recipients of the Amgen Award for Science Teaching Excellence. The award recognizes teachers in grades K-12 whose dedication to students has had a significant impact on the learning and interest of the futu... |
| | | 06/08/09 | Amgen to Present at the Goldman Sachs Global Healthcare Conference| THOUSAND OAKS, Calif., June 8 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN) will present at the Goldman Sachs Global Healthcare Conference on
Wednesday, June 10, 2009 at the Grand Hyatt, New York City, N.Y., beginning at
9:00 a.m. Eastern Time. Roger M. Perlmutter, Amgen's Executive Vice President
of Research & Development, will present. Live audio of the presentation will
be available over the Internet and can be accessed from Amgen's Web site,
www.amgen.com, under Investors.
I... |
| | | 06/07/09 | New Study Shows Nplate(R) Significantly Reduces Splenectomy Rate and Treatment Failure in Patients With Chronic ITP| BERLIN, June 7 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today
released the results of a new study comparing Nplate(R) (romiplostim) to the
medical standard of care (SOC) in non-splenectomised adult patients with
chronic immune thrombocytopenic purpura (ITP). Chronic ITP is a serious
autoimmune disorder characterised by low platelet counts in the blood
(thrombocytopenia), which can lead to serious bleeding events. The study
results show Nplate significantly reduced the incid... |
| | | 05/27/09 | VIDEO from Medialink and Amgen: New Survey Highlights Growing Concern About Risk of Infection and Emerging Antibiotic Resistance in Cancer Patients| --Amgen, CDC Foundation and CDC Partner to Launch Three-Year Initiative to Improve Infection Control in Vulnerable Cancer Patient PopulationTHOUSAND OAKS, Calif., May 27, 2009 /PRNewswire via COMTEX/ -- Amgen (Nasdaq: AMGN) today announced the results of a national Harris Interactive, Inc. survey indicating that the vast majority of oncologists, and infectious disease (ID) specialists are highly concerned about the negative impact infection may have on treatment outcomes, as well as emerging ant... |
| | | 05/27/09 | New Survey Highlights Growing Concern About Risk of Infection in Cancer Patients and Emerging Antibiotic Resistance| --Amgen, CDC Foundation and CDC Partner to Launch Three-Year Initiative to Improve Infection Control in Vulnerable Cancer Patient PopulationTHOUSAND OAKS, Calif., May 27, 2009 /PRNewswire-FirstCall via COMTEX/ -- Amgen (Nasdaq: AMGN) today announced the results of a national Harris Interactive, Inc. survey indicating that the vast majority of oncologists and infectious disease (ID) specialists are highly concerned about the negative impact infection may have on treatment outcomes in chemotherapy... |
| | | 05/26/09 | Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452| Cytokinetics Receives Exercise Fee of $50 Million;
Cytokinetics to Host a Conference Call Tuesday, May 26, 2009 at 9 AM ET
SOUTH SAN FRANCISCO, Calif. and THOUSAND OAKS, Calif., May 26
/PRNewswire-FirstCall/ -- Cytokinetics Incorporated (Nasdaq: CYTK) and Amgen
Inc. (Nasdaq: AMGN) today announced that Amgen has exercised its option to
obtain an exclusive license, worldwide (excluding Japan), to Cytokinetics'
cardiac contractility program. The license includes CK-1827452, a... |
| | | 05/15/09 | Amgen Highlights Data to Be Presented at ASCO| New Vectibix(R) (Panitumumab) Combination Chemotherapy Data
New Data Reinforce Importance of Infection Prevention in Chemotherapy
Patients
Oncology Pipeline Continues to Advance With New Data in Multiple Tumor
Types
THOUSAND OAKS, Calif., May 15 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN) today announced it will present new data from the Company's oncology
portfolio of approved and investigational cancer products at the 2009 American
Society of Clinical Oncology (ASCO)... |
| | | 05/13/09 | Amgen to Present at the Deutsche Bank 34th Annual Healthcare Conference| THOUSAND OAKS, Calif., May 13 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN) will present at the Deutsche Bank 34th Annual Healthcare Conference on
Monday, May 18, 2009 at the InterContinental, Boston, Mass., beginning at 9:20
a.m. Eastern Time. Chairman and Chief Executive Officer Kevin Sharer will
present. Live audio of the presentation will be available over the Internet
and can be accessed from Amgen's Web site, www.amgen.com, under Investors.
Information regarding presentati... |
| | | 05/06/09 | Amgen Announces Voting Results Of Annual Meeting Of Stockholders| THOUSAND OAKS, Calif., May 6 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN), today announced results of voting at the company's Annual Meeting of
Stockholders, held at The St. Regis Hotel, San Francisco, Calif.
Approximately 87.3 percent of outstanding shares were represented at the
meeting.
The director nominees: David Baltimore, Frank J. Biondi, Jr., Francois de
Carbonnel, Jerry D. Choate, Vance D. Coffman, Frederick W. Gluck, Frank C.
Herringer, Gilbert S. Omenn, Judith C. Pe... |
| | | 04/30/09 | Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign|
'Coping with Cancer from the Outside In' Program to Launch at the Annual
Oncology Nursing Society Congress
THOUSAND OAKS, Calif., April 30 /PRNewswire-FirstCall/ -- Amgen and
ONSEdge, a subsidiary of the Oncology Nursing Society (ONS), today announced
that they will partner alongside celebrity make-up artist and cancer survivor
Jan Ping to support a new educational campaign, Coping with Cancer From the
Outside In. The initiative is aimed at educating oncology nurses about the
sk... |
| | | 04/30/09 | Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign|
"Coping with Cancer from the Outside In" Program to Launch at the Annual
Oncology Nursing Society Congress
THOUSAND OAKS, Calif., April 30 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN) and ONSEdge, a subsidiary of the Oncology Nursing Society (ONS), today
announced that they will partner alongside celebrity make-up artist and cancer
survivor Jan Ping to support a new educational campaign, Coping with Cancer
From the Outside In. The initiative is aimed at educating oncology nurse... |
| | | 04/23/09 | Amgen's First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percent to $1.08| First Quarter 2009 Revenue Decreased 8 Percent to $3.3 Billion
First Quarter 2009 GAAP Earnings Per Share Decreased 3 Percent to $0.98
2009 Total Revenue Guidance Range Lowered from $14.8 to $15.2 Billion to
$14.4 to $14.8 Billion
2009 Adjusted Earnings Per Share Guidance Range Maintained at $4.55 to
$4.75
THOUSAND OAKS, Calif., April 23 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN) reported adjusted earnings per share (EPS) of $1.08 for the first
quarter of... |
| | | 04/20/09 | Amgen Announces Webcast of 2009 First Quarter Financial Results| THOUSAND OAKS, Calif., April 20 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN) today announced that it plans to report its first quarter financial
results on Thursday, April 23, 2009 after the close of the financial markets.
The announcement will be followed by a conference call with the investment
community at 2 p.m. Pacific Time. Participating in the call from Amgen will
be Kevin Sharer, chairman and chief executive officer, and other members of
Amgen's senior management team.
... |
| | | 04/16/09 | Preclinical Data From Amgen's Oncology Pipeline to be Presented at AACR| Early Research Suggests that Understanding the Fundamental Mechanism of
Angiogenesis is More Complicated Than Understanding the Function of VEGF - A
Amgen Launches Angiogenesis Website
THOUSAND OAKS, Calif., April 16 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN) today announced that results from several preclinical studies
investigating potential new cancer agents will be presented at the 2009
American Association for Cancer Research (AACR) Annual Meeting in Denver
between Ap... |
| | | 03/30/09 | Amgen to Present at the Citigroup Biotech Day| THOUSAND OAKS, Calif.,
March 30
/PRNewswire-FirstCall/ --
Amgen
(Nasdaq:
AMGN) will present at
Citigroup's
4th Annual Biotech Day on
Wednesday, April
1, 2009
at the Citigroup Conference Center,
New York, N.Y.
, beginning at
11:20
a.m. Eastern Time
. Amgen Vice President of Investor Relations Arvind Sood
will present. Live audio of the presentation will be available over the
Internet and can be accessed from
Amgen's
... |
| | | 03/16/09 | Amgen to Present at the Cowen and Company Annual Healthcare Conference| THOUSAND OAKS, Calif., March 16 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN) will present at the Cowen and Company Annual Healthcare Conference on
Wednesday, March 18, 2009 at the Boston Marriott Copley Place, Boston, Mass.,
beginning at 9:30 a.m. Eastern Time. James Daly, Amgen's Senior Vice
President of North American Commercial Operations, will present. Live audio of
the presentation will be available over the Internet and can be accessed from
Amgen's Web site, www.amgen.com, un... |
| | | 03/09/09 | Amgen to Present at the Barclays Capital Global Healthcare Conference| THOUSAND OAKS, Calif., March 9 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN) will present at the Barclays Capital Global Healthcare Conference on
Wednesday, March 11, 2009 at the Loews Miami Beach Hotel, Miami Beach, Fla.,
beginning at 9:00 a.m. Eastern Time. Amgen's Chief Financial Officer Robert
A. Bradway will present. Live audio of the presentation will be available over
the Internet and can be accessed from Amgen's Web site, www.amgen.com, under
Investors.
Information regar... |
| | | 03/04/09 | "Project Runway's" Tim Gunn Launches Addressing Psoriasis(TM) Campaign to Advocate that Patients Shouldn't Let Psoriasis Impact Personal Style| -- Campaign Sponsored by Amgen and Wyeth Offers Chance to Win a Walk on the Runway in New York City Fashion Show
NEW YORK, March 4, 2009 /PRNewswire-FirstCall via COMTEX/ -- Campaign Sponsored by Amgen and Wyeth Offers a Chance to Win a Walk on the Runway in New York City Fashion Show
Amgen and Wyeth today announced that they have partnered with Tim Gunn, television host and fashion consultant ("Project Runway," "Tim Gunn's Guide to Style") to launch Addressing Psoriasis(TM), an awareness camp... |
| | | 02/18/09 | FDA Accepts Amgen's Submission and Files Biologics License Application for Denosumab| THOUSAND OAKS, Calif., Feb. 18 /PRNewswire-FirstCall/ -- Amgen Inc.
(Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration
(FDA) has accepted Amgen's submission and filed a Biologics License
Application (BLA) for denosumab, an investigational RANK Ligand inhibitor.
The indications for which Amgen is seeking FDA approval are treatment and
prevention of postmenopausal osteoporosis (PMO) in women and treatment and
prevention of bone loss in patients undergoing hormone a... |
| | | 02/11/09 | Independent Data Monitoring Committee Recommends Resuming Enrollment of Non-Squamous NSCLC Patients in the Motesanib MONET1 Trial| THOUSAND OAKS, Calif. and CAMBRIDGE, Mass., Feb. 11 and OSAKA, Japan (Feb.
12, 2009) /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN), Millennium: The
Takeda Oncology Company, and its parent company Takeda Pharmaceutical Company
Limited (TSE:4052) today announced the Independent Data Monitoring Committee
(DMC) for the MONET1 trial has recommended the trial resume enrollment of
patients with non-squamous non-small cell lung cancer (NSCLC) following a
three-month enrollment suspension. MON... |
| | | 02/06/09 | Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)| First and Only Approved Platelet Producer in Europe Represents New
Treatment Approach for Serious Chronic Autoimmune Disorder
ZUG, Switzerland, Feb. 6 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN)
today announced that the European Commission (EC) has granted marketing
authorisation for Nplate(R) (romiplostim) for the treatment of splenectomised
adult chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients who
are refractory to other treatments (e.g. corticosteroids, im... |
| | | 01/26/09 | Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55| Full Year 2008 Revenue Increased 2 Percent to $15.0 Billion; Fourth
Quarter 2008 Revenue Flat at $3.75 Billion
Full Year 2008 GAAP Earnings Per Share Increased 38 Percent to $3.90;
Fourth Quarter 2008 GAAP Earnings Per Share Increased 20 Percent to $0.91
2009 Total Revenue Expected to be in the Range of $14.8 to $15.2 Billion
2009 Adjusted Earnings Per Share Expected to be in the Range of $4.55 to
$4.75
THOUSAND OAKS, Calif., Jan. 26 /PRNewswire-FirstCall/ -- Amgen (Na... |
| | | 01/22/09 | Amgen's Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services| THOUSAND OAKS, Calif., Jan. 22 /PRNewswire-FirstCall/ -- In an ongoing
effort to raise awareness of the comprehensive continuum of resources
available to cancer patients and their caregivers -- from prevention to
education, patient care to advocacy and financial support --Amgen's Breakaway
from Cancer(TM) initiative has expanded its charitable partners to now include
the National Coalition for Cancer Survivorship, Patient Advocate Foundation,
Prevent Cancer Foundation and The Wellness ... |
| | | 01/20/09 | Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results| THOUSAND OAKS, Calif., Jan. 20 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN) today announced that it plans to report its fourth quarter and full year
financial results on Monday, Jan. 26, 2009 after the close of the financial
markets. The announcement will be followed by a conference call with the
investment community at 2:00 p.m. Pacific Time. Participating in the call
from Amgen will be Kevin Sharer, chairman and chief executive officer, and
other members of Amgen's senior manageme... |
| | | 01/07/09 | Amgen to Present at the 27th Annual JP Morgan Healthcare Conference| THOUSAND OAKS, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN) will present at the 27th Annual JP Morgan Global Healthcare Conference
at 9:00 a.m. Pacific Time on Monday, Jan. 12, 2009, at the Westin St. Francis
in San Francisco, Calif. Amgen Chairman and CEO Kevin Sharer will present at
the conference. Live audio of the presentation will be available over the
Internet and can be accessed from Amgen's Web site, www.amgen.com, under
Investors.
(Logo: http://www.ne... |
| |
|
